Education
About Us
Working with TipRanks
Follow Us
RedHill Biopharma (RDHL)
NASDAQ:RDHL
RDHL Stock Chart & Stats
$1.20
-$0.32(-4.91%)
At close: 4:00 PM EST
$1.20
-$0.32(-4.91%)
Day’s Range― - ―
52-Week Range$0.88 - $3.47
Previous CloseN/A
Volume5.64K
Average Volume (3M)1.98M
Market Cap
$4.79M
Enterprise Value$428.12K
Total Cash (Recent Filing)$2.87M
Total Debt (Recent Filing)$214.00K
Price to Earnings (P/E)―
Beta1.41
Next Earnings
Mar 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.32
Shares Outstanding5,112,885
10 Day Avg. Volume104,605
30 Day Avg. Volume1,981,143
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-3.27
Price to Sales (P/S)1.90
P/FCF Ratio-1.63
Enterprise Value/Market Cap0.09
Enterprise Value/Revenue0.04
Enterprise Value/Gross Profit0.07
Enterprise Value/Ebitda-0.05
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)$50.60M
Bulls Say, Bears Say
Bulls Say
RHB-102 Development Via FDA 505(b)(2) For GLP-1 GI Side EffectsPursuing RHB-102 under 505(b)(2) targets GI side effects of GLP-1/GIP therapies, a structural market need. A successful approval could reduce GLP-1 discontinuation, broaden commercial partners, and provide faster, lower‑risk regulatory path and sustainable revenue streams over the medium term.
Opaganib Shows In Vivo Efficacy As Oncology Add-onDemonstrated preclinical ability to resensitize venetoclax‑resistant CLL positions opaganib as a durable oncology add‑on opportunity. Coupled with existing safety data and ongoing phase 2 work, this expands the pipeline's commercial and partnership appeal across resistance-driven oncology niches.
Talicia Joint Venture With Cumberland Boosts Commercialization ResourcesThe Talicia JV shifts commercialization risk and brings partner capital and U.S. co‑commercialization capabilities. This structural change can improve market execution, revenue share predictability and regulatory/listing compliance while allowing RedHill to reallocate resources to other pipeline priorities.
Bears Say
Negative Equity And Prior High LeveragePersistent negative equity and historically high leverage constrain financial flexibility, raise refinancing and covenant risk, and limit capacity to invest in launches or trials. Such structural balance‑sheet weakness increases vulnerability to adverse outcomes and raises long‑term financing costs.
Ongoing Negative Operating And Free Cash FlowsChronic negative operating and free cash flow mean RedHill must repeatedly access external capital to fund operations and trials. This structural cash deficit constrains organic growth, forces dilution or debt reliance, and limits the company's ability to self‑fund commercialization or larger clinical programs.
Reliance On Dilutive Financing FacilitiesDependence on standby equity facilities and ATM offerings signals a structural funding gap. While providing liquidity, these mechanisms are dilutive and can recur, reducing existing shareholders' stakes and potentially undermining long‑term capital stability if operating cash generation doesn't improve.
RedHill Biopharma News
RDHL FAQ
What was RedHill Biopharma’s price range in the past 12 months?
RedHill Biopharma lowest stock price was $0.88 and its highest was $3.47 in the past 12 months.
What is RedHill Biopharma’s market cap?
RedHill Biopharma’s market cap is $4.79M.
When is RedHill Biopharma’s upcoming earnings report date?
RedHill Biopharma’s upcoming earnings report date is Mar 12, 2026 which is in 7 days.
How were RedHill Biopharma’s earnings last quarter?
RedHill Biopharma released its earnings results on Sep 05, 2025. The company reported -$2.318 earnings per share for the quarter, missing the consensus estimate of N/A by -$2.318.
Is RedHill Biopharma overvalued?
According to Wall Street analysts RedHill Biopharma’s price is currently Overvalued.
Does RedHill Biopharma pay dividends?
RedHill Biopharma does not currently pay dividends.
What is RedHill Biopharma’s EPS estimate?
RedHill Biopharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does RedHill Biopharma have?
RedHill Biopharma has 5,112,885 shares outstanding.
What happened to RedHill Biopharma’s price movement after its last earnings report?
RedHill Biopharma reported an EPS of -$2.318 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 16.26%.
Which hedge fund is a major shareholder of RedHill Biopharma?
Currently, no hedge funds are holding shares in RDHL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
RedHill Biopharma
RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on the development and commercialization of innovative therapies for gastrointestinal diseases and cancer. The company operates primarily in the biopharmaceutical sector, with a strong emphasis on creating oral drug formulations that address unmet medical needs. RedHill's core products include therapies targeting conditions such as peptic ulcers, inflammatory bowel disease, and other gastrointestinal disorders, as well as oncology treatments.
Technical Analysis
China Pharma Holdings
―
Sonoma Pharmaceuticals
―
PainReform
―
Universe Pharmaceuticals
―
Shuttle Pharmaceuticals Holdings, Inc.
―
Ownership Overview
―
Insiders
9.25% Other Institutional Investors
90.75% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---